Radioimmunotherapy for Treatment of Acute Leukemia.

Abstract

Acute leukemias are characterized by accumulation of immature cells (blasts) and reduced production of healthy hematopoietic elements. According to the lineage origin, two major leukemias can be distinguished: acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL). Although the survival rate for pediatric ALL is close to 90%, half of the young adults with AML or ALL and approximately 90% of older patients with AML or ALL still die of their disease, raising the need for innovative therapeutic approaches. As almost all leukemic blasts express specific surface antigens, targeted immunotherapy appears to be particularly promising. However, published results of immunotherapy alone are generally modest. Radioimmunotherapy (RIT) brings additional therapeutic mechanisms using radiolabeled monoclonal antibodies (mAbs) directed to tumor antigens, thus adding radiobiological cytotoxicity to immunologic cytotoxicity. Because of the high radiosensitivity of tumor cells and the diffuse widespread nature of the disease, making it rapidly accessible to circulating radiolabeled mAbs, acute leukemias represent relevant indications for RIT. With the development of recombinant and humanized mAbs, innovative radionuclides, and more efficient radiolabeling and pretargeting techniques, RIT has significantly improved over the last 10 years. Different approaches of α and β RIT targeting CD22, CD33, CD45, or CD66 antigens have already been evaluated or are currently being developed in the treatment of acute leukemia. This review summarizes the preclinical and clinical studies demonstrating the potential of RIT in treatment of AML and ALL.

• Authors: Caroline Bodet-Milin, Françoise Kraeber-Bodéré, Thomas Eugène, François Guérard, Joëlle Gaschet, Clément Bailly, Marie Mougin, Mickaël Bourgeois, Alain Faivre-Chauvet, Michel Chérel, Patrice Chevallier
• Journal: Seminars in nuclear medicine (Semin Nucl Med) Vol. 46 Issue 2 Pg. 135-46 (Mar 2016) ISSN: 1558-4623 [Electronic] United States
• PMID: 26897718 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2016 Elsevier Inc. All rights reserved.

Chemical References

• Antigens, CD

Topics

• Acute Disease
• Animals
• Antigens, CD (immunology)
• Humans
• Leukemia (radiotherapy)
• Radioimmunotherapy (methods)